TGX-221PI3Kβ inhibitor,potent,selective and ATP competitive CAS# 663619-89-4 |
- ZSTK474
Catalog No.:BCC3657
CAS No.:475110-96-4
- PIK-90
Catalog No.:BCC1248
CAS No.:677338-12-4
- CAL-101 (Idelalisib, GS-1101)
Catalog No.:BCC1270
CAS No.:870281-82-6
- GDC-0941
Catalog No.:BCC3626
CAS No.:957054-30-7
- GDC-0941 dimethanesulfonate
Catalog No.:BCC1590
CAS No.:957054-33-0
- NVP-QAV-572
Catalog No.:BCC4181
CAS No.:957209-68-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 663619-89-4 | SDF | Download SDF |
| PubChem ID | 9907093 | Appearance | Powder |
| Formula | C21H24N4O2 | M.Wt | 364.44 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 33.33 mg/mL (91.46 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | 9-(1-anilinoethyl)-7-methyl-2-morpholin-4-ylpyrido[1,2-a]pyrimidin-4-one | ||
| SMILES | CC1=CN2C(=O)C=C(N=C2C(=C1)C(C)NC3=CC=CC=C3)N4CCOCC4 | ||
| Standard InChIKey | CPRAGQJXBLMUEL-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C21H24N4O2/c1-15-12-18(16(2)22-17-6-4-3-5-7-17)21-23-19(13-20(26)25(21)14-15)24-8-10-27-11-9-24/h3-7,12-14,16,22H,8-11H2,1-2H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent and selective PI 3-kinase β inhibitor (IC50 values are 0.007, 0.1, 3.5 and 5 μM for the β, δ, γ and α isoforms, respectively). Shows >1,000-fold selectively for PI 3-kinase β over a range of other kinases. Inhibits thrombus formation in animal models. |
TGX-221 Dilution Calculator
TGX-221 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.7439 mL | 13.7197 mL | 27.4394 mL | 54.8787 mL | 68.5984 mL |
| 5 mM | 0.5488 mL | 2.7439 mL | 5.4879 mL | 10.9757 mL | 13.7197 mL |
| 10 mM | 0.2744 mL | 1.372 mL | 2.7439 mL | 5.4879 mL | 6.8598 mL |
| 50 mM | 0.0549 mL | 0.2744 mL | 0.5488 mL | 1.0976 mL | 1.372 mL |
| 100 mM | 0.0274 mL | 0.1372 mL | 0.2744 mL | 0.5488 mL | 0.686 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
TGX-221 is a potent inhibitor of (phosphatidylinositol 3-kinases) PI3K which specifically inhibits PI3K -p110β isoform with IC50 value of 8.5 nM [1].
In J774.2 macrophage cells, TGX-221 has been demonstrated to reduce insulin-induced phosphorylation of Ser473?of protein kinase B (PKB). While in in CHO-IR and 3T3-L1 cells, TGX-221 has no effect on PKB phosphprylation [1].
In vivo, TGX-221 significantly improved blood flow in FeCl3-induced arterial thrombosis as well as?increased tail and renal bleeding times in mice. In addition, TGX-221 has revealed to disrupt CFRs in a Folts model of arterial thrombosis in male Sprague-Dawley rats [2].?
References:
[1] Chaussade C1,?Rewcastle GW,?Kendall JD,?Denny WA,?Cho K,?Gr?nning LM,?Chong ML,?Anagnostou SH,Jackson SP,?Daniele N,?Shepherd PR.
Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J.?2007 Jun 15;404(3):449-58.
[2] Bird JE1,?Smith PL,?Bostwick JS,?Shipkova P,?Schumacher WA.Bleeding response induced by anti-thrombotic doses of a phosphoinositide 3-kinase (PI3K)-β inhibitor in mice. Thromb Res.?2011 Jun;127(6):560-4.
- Ranitidine Hydrochloride
Catalog No.:BCC4533
CAS No.:66357-59-3
- Ranitidine
Catalog No.:BCC9134
CAS No.:66357-35-5
- 5'-Deoxy-5-fluorocytidine
Catalog No.:BCC8746
CAS No.:66335-38-4
- Dihydroguaiaretic acid
Catalog No.:BCN4212
CAS No.:66322-34-7
- ML 171
Catalog No.:BCC6252
CAS No.:6631-94-3
- 3H-1,2-Benzodithiol-3-one-1,1-dioxide
Catalog No.:BCC8633
CAS No.:66304-01-6
- Pregomisin
Catalog No.:BCN7000
CAS No.:66280-26-0
- Gomisin J
Catalog No.:BCN2270
CAS No.:66280-25-9
- 4-Amino-2-methylquinoline
Catalog No.:BCC8677
CAS No.:6628-04-2
- 6'-O-Acetylpaniculoside II
Catalog No.:BCC8316
CAS No.:
- Stemonidine
Catalog No.:BCC8253
CAS No.:66267-46-7
- N-dotriacontanol
Catalog No.:BCC8218
CAS No.:6624-79-9
- Methylsyringol
Catalog No.:BCN3535
CAS No.:6638-05-7
- (+)-Apogossypol
Catalog No.:BCC5585
CAS No.:66389-74-0
- Chloranthalactone A
Catalog No.:BCN8022
CAS No.:66395-02-6
- Chloranthalactone B
Catalog No.:BCN8020
CAS No.:66395-03-7
- 5alpha-Hydroxychloranthalactone A
Catalog No.:BCN7469
CAS No.:66395-04-8
- Pamoic acid disodium salt
Catalog No.:BCC7909
CAS No.:6640-22-8
- 13-Hydroxyoxyberberine
Catalog No.:BCN3355
CAS No.:66408-27-3
- 6-Amino-1,3-dimethyluracil
Catalog No.:BCC8755
CAS No.:6642-31-5
- 2-(2,4-Diaminophenoxy)ethanol dihydrochloride
Catalog No.:BCN8497
CAS No.:66422-95-5
- Kaempferol 3-O-(6''-O-acetyl)glucoside-7-O-rhamnoside
Catalog No.:BCN1385
CAS No.:66465-24-5
- H-D-Lys(Boc)-OMe.HCl
Catalog No.:BCC2990
CAS No.:66494-53-9
- JW 55
Catalog No.:BCC2453
CAS No.:664993-53-7
Activation of phosphatidylinositol 3-kinase beta by the platelet collagen receptors integrin alpha2beta1 and GPVI: The role of Pyk2 and c-Cbl.[Pubmed:25960397]
Biochim Biophys Acta. 2015 Aug;1853(8):1879-88.
Phosphatidylinositol 3-kinasebeta (PI3Kbeta) plays a predominant role in integrin outside-in signaling and in platelet activation by GPVI engagement. We have shown that the tyrosine kinase Pyk2 mediates PI3Kbeta activation downstream of integrin alphaIIbbeta3, and promotes the phosphorylation of the PI3K-associated adaptor protein c-Cbl. In this study, we compared the functional correlation between Pyk2 and PI3Kbeta upon recruitment of the two main platelet collagen receptors, integrin alpha2beta1 and GPVI. PI3Kbeta-mediated phosphorylation of Akt was inhibited in Pyk2-deficient platelets adherent to monomeric collagen through integrin alpha2beta1, but occurred normally upon GPVI ligation. Integrin alpha2beta1 engagement led to Pyk2-independent association of c-Cbl with PI3K. However, c-Cbl was not phosphorylated in adherent platelets, and phosphorylation of Akt occurred normally in c-Cbl-deficient platelets, indicating that the c-Cbl is dispensable for Pyk2-mediated PI3Kbeta activation. Stimulation of platelets with CRP, a selective GPVI ligand, induced c-Cbl phosphorylation in the absence of Pyk2, but failed to promote its association with PI3K. Pyk2 activation was completely abrogated in PI3KbetaKD, but not in PI3KgammaKD platelets, and was strongly inhibited by Src kinases and phospholipase C inhibitors, and by BAPTA-AM. The absence of PI3Kbeta activity also hampered GPVI-induced tyrosine-phosphorylation and activation of PLCgamma2, preventing intracellular Ca2+ increase and phosphorylation of pleckstrin. Moreover, GPVI-induced intracellular Ca2+ increase and pleckstrin phosphorylation were also strongly inhibited in human platelets treated with the PI3Kbeta inhibitor TGX-221. These results outline important differences in the regulation of PI3Kbeta by GPVI and integrin alpha2beta1 and suggest that inhibition of Pyk2 may target PI3Kbeta activation in a selective context of platelet stimulation.
Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils.[Pubmed:15878979]
Blood. 2005 Aug 15;106(4):1432-40.
It is well established that preexposure of human neutrophils to proinflammatory cytokines markedly augments the production of reactive oxygen species (ROS) to subsequent stimuli. This priming event is thought to be critical for localizing ROS to the vicinity of the inflammation, maximizing their role in the resolution of the inflammation, and minimizing the damage to surrounding tissue. We have used a new generation of isoform-selective phosphoinositide 3-kinase (PI3K) inhibitors to show that ROS production under these circumstances is regulated by temporal control of class I PI3K activity. Stimulation of tumor necrosis factor-alpha (TNF-alpha)-primed human neutrophils with N-formyl-methionyl-leucyl-phenylalanine (fMLP) results in biphasic activation of PI3K; the first phase is largely dependent on PI3Kgamma, and the second phase is largely dependent on PI3Kdelta. The second phase of PI3K activation requires the first phase; it is this second phase that is augmented by TNF-alpha priming and that regulates parallel activation of ROS production. Surprisingly, although TNF-alpha-primed mouse bone marrow-derived neutrophils exhibit superficially similar patterns of PI3K activation and ROS production in response to fMLP, these responses are substantially lower and largely dependent on PI3Kgamma alone. These results start to define which PI3K isoforms are responsible for modulating neutrophil responsiveness to infection and inflammation.
PI 3-kinase p110beta: a new target for antithrombotic therapy.[Pubmed:15834429]
Nat Med. 2005 May;11(5):507-14.
Platelet activation at sites of vascular injury is essential for the arrest of bleeding; however, excessive platelet accumulation at regions of atherosclerotic plaque rupture can result in the development of arterial thrombi, precipitating diseases such as acute myocardial infarction and ischemic stroke. Rheological disturbances (high shear stress) have an important role in promoting arterial thrombosis by enhancing the adhesive and signaling function of platelet integrin alpha(IIb)beta(3) (GPIIb-IIIa). In this study we have defined a key role for the Type Ia phosphoinositide 3-kinase (PI3K) p110beta isoform in regulating the formation and stability of integrin alpha(IIb)beta(3) adhesion bonds, necessary for shear activation of platelets. Isoform-selective PI3K p110beta inhibitors have been developed which prevent formation of stable integrin alpha(IIb)beta(3) adhesion contacts, leading to defective platelet thrombus formation. In vivo, these inhibitors eliminate occlusive thrombus formation but do not prolong bleeding time. These studies define PI3K p110beta as an important new target for antithrombotic therapy.
